Loomis Sayles & Co. L P decreased its holdings in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 38.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 319,666 shares of the company's stock after selling 202,443 shares during the quarter. Loomis Sayles & Co. L P owned 0.57% of Astrana Health worth $10,079,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in shares of Astrana Health by 136.1% in the fourth quarter. JPMorgan Chase & Co. now owns 163,532 shares of the company's stock valued at $5,156,000 after acquiring an additional 94,268 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Astrana Health by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 4,685,959 shares of the company's stock valued at $147,748,000 after purchasing an additional 20,757 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Astrana Health during the 4th quarter worth $318,000. Quantbot Technologies LP raised its position in shares of Astrana Health by 152.5% during the 4th quarter. Quantbot Technologies LP now owns 10,651 shares of the company's stock valued at $336,000 after acquiring an additional 6,433 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in shares of Astrana Health by 415.3% in the 4th quarter. Teacher Retirement System of Texas now owns 81,207 shares of the company's stock valued at $2,560,000 after purchasing an additional 65,449 shares during the period. Institutional investors and hedge funds own 52.77% of the company's stock.
Analysts Set New Price Targets
A number of analysts have recently commented on ASTH shares. Macquarie raised Astrana Health to a "hold" rating in a research note on Monday, December 16th. Barclays began coverage on shares of Astrana Health in a research note on Tuesday. They issued an "equal weight" rating and a $36.00 target price for the company. Truist Financial cut their target price on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Bank of America decreased their price target on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Finally, Robert W. Baird lowered their price objective on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Astrana Health has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.
Read Our Latest Stock Report on ASTH
Astrana Health Stock Down 0.8 %
Shares of ASTH stock traded down $0.23 on Thursday, hitting $29.79. 61,583 shares of the stock were exchanged, compared to its average volume of 263,209. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.49 billion, a P/E ratio of 22.92, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. Astrana Health, Inc. has a fifty-two week low of $23.12 and a fifty-two week high of $63.20. The business has a 50-day moving average of $33.47 and a 200 day moving average of $41.49.
Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. Equities analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current year.
Astrana Health Company Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
See Also
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
